Establishing Clinically Relevant Severity Levels for the Central Sensitization Inventory. Issue 2 (15th March 2016)

• Record Type: Journal Article
• Authors: Neblett, Randy; Hartzell, Meredith M.; Mayer, Tom G.; Cohen, Howard; Gatchel, Robert J.
• Is Part Of: Pain practice. Volume 17:Issue 2(2017:Feb.)
• Page Start: 166
• Page End: 175
• Publication Date: 2016-03-15
• Subjects: central sensitization inventory -- central sensitization -- central sensitivity syndrome -- chronic pain; Pain -- Treatment -- Periodicals; 616.0472
• DOI: 10.1111/papr.12440
• Languages: English
• ISSNs: 1530-7085

Abstract

Abstract: Objectives: The aim of this study was to create and validate severity levels for the central sensitization inventory (CSI), a valid and reliable patient‐reported outcome instrument designed to identify patients whose presenting symptoms may be related to a central sensitivity syndrome (CSS; eg, fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome), with a proposed common etiology of central sensitization (CS). Methods: Based on CSI score means and standard deviations from previously published subject samples, the following CSI severity levels were established: subclinical = 0 to 29; mild = 30 to 39; moderate = 40 to 49; severe = 50 to 59; and extreme = 60 to 100. The concurrent validity of the CSI severity levels was then confirmed in a separate chronic pain patient sample (58% with a CSS diagnosis and 42% without) by demonstrating associations between CSI scores and (1) the number of physician‐diagnosed CSSs; (2) CSI score distributions in both CSS and non‐CSS patient samples; (3) patient‐reported history of CSSs; and (4) patient‐reported psychosocial measures, which are known to be associated with CSSs. Results: Compared to the non‐CSS patient subsample, the score distribution of the CSS patient subsample was skewed toward the higher severity ranges. CSI mean scores moved into higher severity levels as the number of individual CSS diagnoses increased. Patients who scored in the extreme CSI severity level were more likely to report previous diagnoses of fibromyalgia, chronic fatigue syndrome, temporomandibular joint disorder, tension/migraine headaches, and anxiety or panic attacks ( P < 0.01). CSI severity levels were also associated with patient‐reported depressive symptoms, perceived disability, sleep disturbance, and pain intensity ( P ≤ 0.02). Conclusion: This study provides support for these CSI severity levels as a guideline for healthcare providers and researchers in interpreting CSI scores and evaluating treatment responsiveness.